CorMedix Inc. (CRMD)
NASDAQ: CRMD · Real-Time Price · USD
5.15
-0.08 (-1.53%)
Nov 6, 2026, 11:56 AM EST - Market open
CorMedix Revenue
CorMedix had revenue of $101.93M in the quarter ending June 30, 2026, with 156.52% growth. This brings the company's total for the last twelve months to $462.25M, up 280.50% year-over-year. In the year 2025, CorMedix had annual revenue of $311.71M with 617.03% growth. That makes CorMedix the 11,709th largest company in the world by revenue and 2,335th in the United States.
Revenue (ttm)
$462.25M
Revenue Growth
+280.50%
P/S Ratio
0.88
Revenue / Employee
$2,420,152
Employees
191
Market Cap
401.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 311.71M | 268.24M | 617.03% |
| Dec 31, 2024 | 43.47M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 65.41K | -125.53K | -65.74% |
| Dec 31, 2021 | 190.94K | -48.30K | -20.19% |
| Dec 31, 2020 | 239.23K | -44.04K | -15.55% |
| Dec 31, 2019 | 283.27K | -146.53K | -34.09% |
| Dec 31, 2018 | 429.80K | 100.47K | 30.51% |
| Dec 31, 2017 | 329.33K | 105.22K | 46.95% |
| Dec 31, 2016 | 224.11K | 13.98K | 6.65% |
| Dec 31, 2015 | 210.13K | 20.86K | 11.02% |
| Dec 31, 2014 | 189.27K | 187.27K | 9,358.97% |
| Dec 31, 2013 | 2.00K | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 303.73M |
| Phathom Pharmaceuticals | 274.88M |
| Prothena Corporation | 54.53M |
| Editas Medicine | 47.01M |
| Prelude Therapeutics | 22.42M |
| YD Bio | 1.24M |
| Oculis Holding AG | 1.12M |
CRMD News
- 3 hours ago - CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 - GlobeNewsWire
- 4 days ago - CorMedix backs FY26 revenue view $325M-$345M, consensus $336.59M - TheFly
- 4 days ago - CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position - GlobeNewsWire
- 18 days ago - CorMedix announces FDA acceptance for Priority Review of Rezzayo sNDA - TheFly
- 18 days ago - Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases - GlobeNewsWire
- 22 days ago - Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer - PRNewsWire
- 6 weeks ago - CorMedix initiated with an Outperform at Oppenheimer - TheFly
- 1 month ago - CorMedix Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts